Literature DB >> 31375764

Ductal carcinoma in situ of the breast: immune cell composition according to subtype.

Marie Colombe Agahozo1, Mieke R van Bockstal2, Floris H Groenendijk2, Thierry P P van den Bosch2, Pieter J Westenend3, Carolien H M van Deurzen2.   

Abstract

Ductal carcinoma in situ of the breast includes several subtypes with a divergent biological behavior. Data regarding the composition of ductal carcinoma in situ-associated immune cells and their potential role in progression is limited. We studied ductal carcinoma in situ-associated immune response by characterizing immune cell subsets according to ductal carcinoma in situ subtypes. Ductal carcinoma in situ-associated tumor infiltrating lymphocyte (TIL) density was evaluated based on hematoxylin and eosin (H&E)-stained sections from 473 patients. Cases were subtyped based on ER, PR, and HER2. Patients were categorized as TIL-high or low. Ductal carcinoma in situ-associated immune cells of TIL-high cases were immunostained on whole slides with CD4, CD8, CD20, CD68, FOXP3, and PD-L1 (SP142 and SP263). In total, 131/473 patients (28.0%) were considered as TIL-high. The percentage of TIL-high cases was significantly higher in HER2+ and triple-negative ductal carcinoma in situ (P < 0.0001). Overall, no statistical difference in immune cell composition according to subtypes was found. However, individual subtype comparison showed that ER+ HER2+ cases had a significantly higher proportion of CD8+ T cells compared with triple-negative cases (P = 0.047). In TIL-high cases, PD-L1-SP142 expression on tumor cells was associated with subtype (P = 0.037); the lowest number of positive cases was observed in the HER2+ subtype (independent of ER). However, in TIL-high ductal carcinoma in situ, PD-L1 expression by both clones was limited. In conclusion, high numbers of TILs are predominantly observed in HER+ and triple negative ductal carcinoma in situ. The ER+ HER2+ subtype seems to attract a higher proportion of CD8+ T cells compared with the triple negative subtype. Among TIL-high cases, the HER2+ subgroup had the lowest PD-L1-SP142 expression on tumor cells. This suggests a more pronounced antitumor immunity in HER2+ ductal carcinoma in situ, which could play a role in its biological behavior.

Entities:  

Year:  2019        PMID： 31375764     DOI： 10.1038/s41379-019-0331-8

Source DB:  PubMed          Journal:  Mod Pathol        ISSN： 0893-3952            Impact factor:   7.842


  37 in total

Review 1.  Ductal carcinoma in situ of the breast.

Authors:  Nicola L P Barnes; Jane L Ooi; John R Yarnold; Nigel J Bundred
Journal:  BMJ       Date:  2012-02-29

Review 2.  Breast cancer precursors revisited: molecular features and progression pathways.

Authors:  Maria A Lopez-Garcia; Felipe C Geyer; Magali Lacroix-Triki; Caterina Marchió; Jorge S Reis-Filho
Journal:  Histopathology       Date:  2010-05-24       Impact factor: 5.087

3.  Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study.

Authors:  Laura C Collins; Rulla M Tamimi; Heather J Baer; James L Connolly; Graham A Colditz; Stuart J Schnitt
Journal:  Cancer       Date:  2005-05-01       Impact factor: 6.860

Review 4.  Ductal carcinoma in situ: risk factors and impact of screening.

Authors:  Beth A Virnig; Shi-Yi Wang; Tatyana Shamilyan; Robert L Kane; Todd M Tuttle
Journal:  J Natl Cancer Inst Monogr       Date:  2010

Review 5.  Next-generation sequencing: a powerful tool for the discovery of molecular markers in breast ductal carcinoma in situ.

Authors:  Hitchintan Kaur; Shihong Mao; Seema Shah; David H Gorski; Stephen A Krawetz; Bonnie F Sloane; Raymond R Mattingly
Journal:  Expert Rev Mol Diagn       Date:  2013-03       Impact factor: 5.225

6.  Effect of three decades of screening mammography on breast-cancer incidence.

Authors:  Archie Bleyer; H Gilbert Welch
Journal:  N Engl J Med       Date:  2012-11-22       Impact factor: 91.245

Review 7.  Clinical relevance of host immunity in breast cancer: from TILs to the clinic.

Authors:  Peter Savas; Roberto Salgado; Carsten Denkert; Christos Sotiriou; Phillip K Darcy; Mark J Smyth; Sherene Loi
Journal:  Nat Rev Clin Oncol       Date:  2015-12-15       Impact factor: 66.675

8.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.

Authors:  A Goldhirsch; E P Winer; A S Coates; R D Gelber; M Piccart-Gebhart; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2013-08-04       Impact factor: 32.976

Review 9.  The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis.

Authors:  Yan Mao; Qing Qu; Xiaosong Chen; Ou Huang; Jiayi Wu; Kunwei Shen
Journal:  PLoS One       Date:  2016-04-13       Impact factor: 3.240

10.  Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials.

Authors:  Vassiliki Kotoula; Kyriakos Chatzopoulos; Sotiris Lakis; Zoi Alexopoulou; Eleni Timotheadou; Flora Zagouri; George Pentheroudakis; Helen Gogas; Eleni Galani; Ioannis Efstratiou; Thomas Zaramboukas; Angelos Koutras; Gerasimos Aravantinos; Epaminontas Samantas; Amanda Psyrri; Helen Kourea; Mattheos Bobos; Pavlos Papakostas; Paris Kosmidis; Dimitrios Pectasides; George Fountzilas
Journal:  Oncotarget       Date:  2016-01-26
View more
  5 in total

Review 1.  Learning to distinguish progressive and non-progressive ductal carcinoma in situ.

Authors:  Anna K Casasent; Mathilde M Almekinders; Charlotta Mulder; Proteeti Bhattacharjee; Deborah Collyar; Alastair M Thompson; Jos Jonkers; Esther H Lips; Jacco van Rheenen; E Shelley Hwang; Serena Nik-Zainal; Nicholas E Navin; Jelle Wesseling
Journal:  Nat Rev Cancer       Date:  2022-10-19       Impact factor: 69.800

2.  Stromal Changes are Associated with High P4HA2 Expression in Ductal Carcinoma in Situ of the Breast.

Authors:  Marie Colombe Agahozo; Mieke van Bockstal; Pieter J Westenend; Christine Galant; Kathleen Lambein; Emily Reisenbichler; Renata Sinke; Serena Wong; Carolien H M van Deurzen
Journal:  J Mammary Gland Biol Neoplasia       Date:  2022-01-25       Impact factor: 2.673

3.  Clinicopathological characteristics and prognostic analysis of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ (DCIS) and DCIS with microinvasion (DCIS-Mi) of the breast.

Authors:  Huiqing Jia; Peng Zhao; Zhaoxu Chen; Guanqun Wang; Xianning Dong; Xiaoming Xing; Xiaohua Tan; Chengqin Wang
Journal:  Breast Cancer Res Treat       Date:  2022-03-08       Impact factor: 4.872

Review 4.  PTEN Dual Lipid- and Protein-Phosphatase Function in Tumor Progression.

Authors:  Anne Liu; Yanyu Zhu; Weiping Chen; Glenn Merlino; Yanlin Yu
Journal:  Cancers (Basel)       Date:  2022-07-28       Impact factor: 6.575

5.  Tumor Infiltrating Lymphocytes in Multi-National Cohorts of Ductal Carcinoma In Situ (DCIS) of Breast.

Authors:  Sunil S Badve; Sanghee Cho; Xiaoyu Lu; Sha Cao; Soumya Ghose; Aye Aye Thike; Puay Hoon Tan; Idris Tolgay Ocal; Daniele Generali; Fabrizio Zanconati; Adrian L Harris; Fiona Ginty; Yesim Gökmen-Polar
Journal:  Cancers (Basel)       Date:  2022-08-13       Impact factor: 6.575
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.